TITLE:  Pulmozyme for Off-Label Indications: Clinical Effectiveness  

DATE:  22 April 2010

RESEARCH QUESTION:

What is the clinical effectiveness of Pulmozyme (dornase alfa) for off-label indications?

METHODS:

A limited literature search was conducted on key health technology assessment resources, including PubMed, the Cochrane Library (Issue 4, 2010), University of York Centre for Reviews and Dissemination (CRD) databases, ECRI (Health Devices Gold), EuroScan, international health technology agencies, and a focused Internet search. The search was limited to English language articles published between 2005 and April 2010. No filters were applied to limit the retrieval by study type. Internet links were provided, where available.

RESULTS:

HTIS reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, controlled clinical trials, and observational studies.

The literature search identified four randomized controlled trials and three observational studies on the clinical effectiveness of Pulmozyme (dornase alfa; rhDNase) for off-label indications. No health technology assessments, systematic reviews, meta-analyses, or controlled clinical trials were identified. Additional articles of potential interest are included in the appendix.
Health technology assessments
No literature identified

Systematic reviews and meta-analyses
No literature identified

Randomized controlled trials


Controlled clinical trials
No literature identified

Observational studies


APPENDIX – FURTHER INFORMATION:

Review articles


Dissertations


Additional references